The 
Introduction

Natriuretic peptides are a family of hormones, sharing similar chemical structure (a characteristic 17-amino acid ring structure, stabilized by a cysteine bridge, which contains several invariant amino acids and variable C-and N-terminal tails) and biological function, with relevant effects in cardiovascular physiology and pathology. The study of natriuretic peptides began 50 years ago, when electron microscopy revealed the presence of secretory granules in cardiac atrial cells containing atrial natriuretic peptide (ANP) as demonstrated by de Bold and coworkers
in the early 80s [1] . From 1988 From to 1990 , two more members of the natriuretic peptide family, the brain natriuretic peptide (BNP) and C-type natriuretic peptide (CNP) were identified in porcine brain [2, 3] .
More recently a new peptide that shares structural and functional characteristics with the previous natriuretic peptides was identified in the venom of the green mamba (Dendroaspis angusticeps) and received the denomination of Dendroaspis natriuretic peptide (DNP) [4]. In addition, other peptides with similar cardiovascular effects have been identified in mammalians, including urodilatin, a peptide derived from alternative cleavage of pro-ANP in the distal
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• Renoprotective effect of natriuretic peptides after acute renal failure • Nesiritide -current benefits/hazards of drug usage tubules of the kidney, where it exerts its natriuretic actions [5] , or the intestinal epithelium derived peptides, guanylin and uroguanylin, which participate in water absorption [6] .
The classic physiological role of natriuretic peptides includes promotion of renal excretion of sodium (natriuresis) and water (diuresis) . Natriuretic peptides also exert autocrine and paracrine effects within circulation, such as vasodilatation by relaxing vascular smooth muscle cells, regulation of renin, progesterone, endothelin and vasopressin secretion [7] .
ANP and BNP are 28-and 32- [11] .
CNP, the third natriuretic peptide identified, is mainly expressed in the nervous system and vascular endothelial cells [14, 15] , where CNP exerts autocrine and paracrine actions on vascular tone and muscle cell growth [15, 16] [15, [18] [19] [20] [21] . DNPlike immunoreactivity has been found in rat aorta, carotid artery and kidney [22, 23] , where it has been found to induce vasorelaxation and inhibition of vascular smooth muscle cell proliferation [23] .
Natriuretic [24, 25] . NPR-A is activated by ANP, BNP and DNP [25, 26] , NPR-B shows high affinity and is activated by CNP and, finally, the NPR-C binds all natriuretic peptides [25] .
NPR [27] . [28, 29] . NPR-C has been involved in peptide clearance, removing natriuretic peptides from the circulation [30] and in the mediation of natriuretic peptide-induced inhibition of cAMP synthesis, an effect that requires the involvement of a heterotrimeric G protein [7, 31, 32] . We [15] . Natriuretic peptides as a 'biomarker' of congestive heart failure and acute renal failure/insufficiency [37, 38] . The sensitivity and specificity of the test is especially high at a cut-off of 76 pg/ml BNP [11] , and NT-proBNP has been proved to be particularly important in decreasing the overdiagnosis of heart failure that occurs in primary care [38] . For NTproBNP, levels over 450 pg/ml (over 900 pg/ml for patients older than 50 years old) are sensitive and specific for heart failure; however, if the value is below 300 pg/ml, heart failure is highly unlikely with a negative predictive value of 99% [39] . In addition, recent studies have reported that BNP is a significant prognostic indicator in patients diagnosed with heart failure and in asymptomatic patients [40] . NT-proBNP has been found to be a stronger risk biomarker for cardiovascular disease and death than C-reactive protein [41] . NT-proBNP [49] . [50] [54] . [55] . Inhibition of neutral endopeptidase increases levels of ANP, BNP and CNP, and has been shown to offer a therapeutic advantage in the treatment of hypertension, heart failure and endothelial dysfunction [56] . Endopeptidase inhibitors reduce vasoconstriction and improve sodium/water balance; as a result these inhibitors decrease peripheral vascular resistance and blood pressure and improve local blood flow [57] . Endopeptidase inhibitors also reduce the activity of the angiotensin-converting enzyme (ACE), leading to a reduction of vasoconstrictor and proliferative mediators, such as angiotensin II and increase local levels of bradykinin [57] . Recent studies have reported that ANP reduces angiotensin II-induced renomedullary interstitial cells proliferation and extracellular matrix synthesis in diabetic subjects more efficiently in neutral endopeptidase-deficient mice, which provide evidence for the beneficial effect of inhibition of neutral endopeptidase in attenuating abnormal cell growth associated with diabetic nephropathy [58] .
NPR-C is a transmembrane receptor with an extracellular domain containing the natriuretic peptide-binding region, a transmembrane domain and a cytosolic domain. Two different subtypes of NPR-C, of approximately 67 and 77 kD in size, have been identified
have provided evidence that the 77 kD NPR-C-like protein is involved in peptide internalization whereas the 67 kD NPR-C-like protein is likely involved in adenylyl cyclase inhibition
In the past decade, much attention has been given to the investigation of natriuretic peptides testing in the evaluation of patients with different pathologies, such as congestive heart failure (CHF). Studies in patients with CHF showed that both ANP and BNP secretion from ventricular myocytes increases in relation to the rigor of dysfunction [10]. These findings led to investigate whether the plasma levels of ANP and BNP may assist in the diagnosis of patients with heart failure. Since half-life of BNP is greater than that of ANP comparison of the diagnostic value of ANP and BNP have generally favoured BNP [33]. As reported above, the inactive N-terminal fragment of BNP, NTproBNP, has an even greater half-life than BNP; thus, most of the clinical investigations concerning natri-
Renoprotective effect of natriuretic peptides after acute renal failure
Natriuretic peptides, especially ANP, have long been reported to have the potential to restore renal function after ischaemic injury, and have been shown to counteract renal sympathetic nerve activity in renal function. ANP overexpression has been shown to exhibit protection against gentamycin-induced nephrotoxicity, as demonstrated by daily subcutaneous administration of gentamycin, for 10 days, in Sprague Dawley rats either treated with an intravenous injection of adenovirus (Ad.RSV-ANP), carrying the human ANP gene, the first day of gentamycin administration, or not treated (control) for comparison. This finding raises the possibility of using ANP gene therapy for the treatment of drug-induced renal failure
Further evidences for the renoprotective role of natriuretic peptides come from studies where the peptide hydrolysis is inhibited. Neutral endopeptidase is an endothelial cell surface zinc metallopeptidase and the major pathway involved in the degradation of the natriuretic peptides
In addition to the renoprotective effect, neutral endopeptidase inhibition, in combination with inhibition of the ACE activity, has been shown to reduce blood pressure in spontaneously hypertensive rats. This is the case of omapatrilat, a potent vasopeptidase inhibitor that exerts anti-hypertensive effects by inhibition of the neutral endopeptidase and ACE at the tissue level, which results in beneficial effects on the cardiovascular structure [59] . The [60] [61] [62] . In addition, nesiritide increases glomerular filtration rate and filtration fraction, suppresses the renin-angiotensin-aldosterone axis, and enhances diuresis and natriuresis [63] . Nesiritide is currently used in the treatment of acute decompensated heart failure, where it has been shown to decrease pulmonary capillary wedge pressure, pulmonary artery pressure, right atrial pressure and systemic vascular resistance, as well as increase cardiac index and stroke volume index [64] [65] [66] .
Nesiritide -current benefits/ hazards of drug usage
Nesiritide is a recombinant form of human BNP and its amino acid sequence is identical to that of endogenous human BNP. Administration of nesiritide results in venous, arterial and coronary vasodilatation, reducing cardiac the pre-load and after-load, which increase cardiac output without direct inotropic effects
In comparison with nitroglycerin, treatment with nesiritide did not induce the appearance of tachyphylaxis and other adverse effects [63] . Unlike [73] . Several studies have reported that an increase in serum creatinine levels, such as that observed with nesiritide, predicts a higher risk of death even when that increase is transient [74, 75] .
Unlike these previous studies, a more recent meta-analysis has reported that nesiritide is not associated with a higher 30-or 180-day mortality [76] . Given the limitations of the meta-analyses, without randomized controlled trials powered to evaluate mortality, Arora and coworkers suggest that it is premature to abandon the use of nesiritide [76] . A summary of the current information concerning the benefits and deleterious effects of the use of nesiritide is provided in Table 1 
